Anti-LPA-3 antibody (ab23692)
Key features and details
- Rabbit polyclonal to LPA-3
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-LPA-3 antibody
See all LPA-3 primary antibodies -
Description
Rabbit polyclonal to LPA-3 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Rat -
Immunogen
Synthetic peptide corresponding to Mouse LPA-3 aa 1-12 (N terminal).
Sequence:MNECHYDKRMDF
-
Positive control
- WB: HepG2 cell lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 50% Glycerol, 0.1% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab23692 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/200. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa).
|
Notes |
---|
WB
1/200. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa). |
Target
-
Function
Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins. -
Tissue specificity
Most abundantly expressed in prostate, testes, pancreas, and heart, with moderate levels in lung and ovary. No detectable expression in brain, placenta, liver, skeletal muscle, kidney, spleen, thymus, small intestine, colon, or peripheral blood leukocytes. -
Sequence similarities
Belongs to the G-protein coupled receptor 1 family. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 23566 Human
- Entrez Gene: 66025 Rat
- Omim: 605106 Human
- SwissProt: Q9UBY5 Human
- SwissProt: Q8K5E0 Rat
- Unigene: 674915 Human
- Unigene: 64507 Rat
-
Alternative names
- Calcium mobilizing lysophosphatidic acid receptor LP A3 antibody
- Calcium mobilizing lysophosphatidic acid receptor LPA 3 antibody
- Calcium mobilizing lysophosphatidic acid receptor LPA3 antibody
see all
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (11)
ab23692 has been referenced in 11 publications.
- Choi SH et al. Visualization of the binding between gintonin, a Panax ginseng-derived LPA receptor ligand, and the LPA receptor subtypes and transactivation of the EGF receptor. J Ginseng Res 46:348-356 (2022). PubMed: 35600777
- Chiang JC et al. Lysophosphatidic acid receptors 2 and 3 regulate erythropoiesis at different hematopoietic stages. Biochim Biophys Acta Mol Cell Biol Lipids 1866:158818 (2021). PubMed: 33035680
- Lee R et al. Effect of the Gintonin-Enriched Fraction on Glucagon-Like-Protein-1 Release. Molecules 26:N/A (2021). PubMed: 34684879
- Wei M et al. Downregulated circular RNA zRANB1 mediates Wnt5a/ß-Catenin signaling to promote neuropathic pain via miR-24-3p/LPAR3 axis in CCI rat models. Gene 761:145038 (2020). PubMed: 32777532
- Li GC et al. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3. J Cell Physiol 234:22331-22342 (2019). PubMed: 31140597